SCHEMBL356172

SCHEMBL356172

CCN1CCC(NC(=O)c2cc(OC3CCc4cc(C(=O)NO)ccc4C3)ccn2)CC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSF1R P07333 1/20 0.43
FLT3 P36888 1/20 0.43
EGLN1 Q9GZT9 1/20 0.40
HDAC8 Q9BY41 7/20 0.40
HDAC6 Q9UBN7 2/20 0.40
SLC6A5 Q9Y345 1/20 0.40
SMYD3 Q9H7B4 1/20 0.39
HRH2 P25021 1/20 0.39
HRH1 P35367 1/20 0.39
MCHR1 Q99705 1/20 0.39
HPGDS O60760 2/20 0.38
MAPKAPK2 P49137 1/20 0.38
KDM4E B2RXH2 1/20 0.38
MEN1 O00255 1/20 0.38
MAPT P10636 1/20 0.38
KMT2A Q03164 1/20 0.38
PRKAB2 O43741 1/20 0.38
CYP3A4 P08684 1/20 0.38
PRKAG1 P54619 1/20 0.38
PRKAA2 P54646 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL355744 0.86 USP30 (0.48) HDAC6MEN1MAPTKMT2A
SCHEMBL354936 0.85 HDAC8 (0.43) CSF1RFLT3HDAC8HDAC6SMYD3
SCHEMBL10283441 0.81 KMT2A (0.44) HDAC8HDAC6KMT2A
SCHEMBL10249770 0.80 HDAC8 (0.43) HDAC8HDAC6
SCHEMBL355960 0.79 FGFR1 (0.39) CSF1RFLT3HDAC8HDAC6
SCHEMBL354020 0.78 USP30 (0.48) MEN1MAPTKMT2A
SCHEMBL10247073 0.76 HDAC8 (0.48) HDAC8HDAC6
SCHEMBL15968937 0.76 HDAC6 (0.44) HDAC8HDAC6
SCHEMBL355710 0.75 HDAC8 (0.48) HDAC8HDAC6
SCHEMBL355819 0.74 FAAH (0.38) KDM4EMEN1MAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140243335-A1 SUBSTITUTED HYDOXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2014-08-28 US disclosed
US-20140243335-A1 SUBSTITUTED HYDOXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2014-08-28 US disclosed
US-20120015943-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACUTICALS, INC. (US) 2012-01-19 US disclosed
US-20120015943-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACUTICALS, INC. (US) 2012-01-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120015943-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF HDAC6, HDAC1, HDAC2 CSF1R 925/4885FLT3 273/4885EGLN1 305/4885
US-20140243335-A1 SUBSTITUTED HYDOXAMIC ACIDS AND USES THEREOF HDAC6, HDAC1, H1-3 CSF1R 1365/4885FLT3 544/4885EGLN1 88/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.